Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jubilant Life Sciences

    Jump to

    • Dominos likely to have over 10,000 stores in India in next 20 years, says Hari Bhartia of Jubilant

    • Jubilant Life Consolidated December 2020 Net Sales at Rs 1,771.34 crore, down 23.49% Y-o-Y

    • Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher

    • Jubilant Life Sciences raises Rs 90 crore through commercial papers

    • Accumulate Jubilant Life Sciences; target of Rs 752: Prabhudas Lilladher

    • Buy Jubilant Life Sciences; target of Rs 855: Motilal Oswal

    • Buy Jubilant Life Sciences; target of Rs 850: ICICI Direct

    • Jubilant Life Standalone September 2020 Net Sales at Rs 760.75 crore, up 0.42% Y-o-Y

    • Jubilant Life Sciences Q2 net profit declines 10% to Rs 224 crore

    • Jubilant Life Consolidated September 2020 Net Sales at Rs 2,374.89 crore, up 4.81% Y-o-Y

    • Buy Jubilant Life Sciences; target of Rs 975: Motilal Oswal

    • Sell Jubilant Life Sciences; target of Rs 446: Prabhudas Lilladher

    • Hold Jubilant Life Sciences: target of Rs 822: ICICI Securities

    • Jubilant Life Sciences shares fall 5% after Q1 profit tumbles 52%

    • Jubilant Life Sciences presents 1,000 vials of Remdesivir to Uttar Pradesh CM Yogi Adityanath

    • Jubilant Life hits 52-week high on DCGI nod for Remdesivir; Rakesh Jhunjhunwala raises stake in June quarter

    • Jubilant Life share at 52-week high as Rakesh Jhunjhunwala raises stake

    • Buy Jubilant Life Sciences; target of Rs 867: Anand Rathi

    • Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher

    • Jubilant Life Consolidated March 2020 Net Sales at Rs 2,391.41 crore, up 0.24% Y-o-Y

    • Jubilant Life Standalone March 2020 Net Sales at Rs 791.36 crore, down 8.53% Y-o-Y

    • Buy Jubilant Life Sciences; target of Rs 550: ICICI Direct

    • Buy Jubilant Life Sciences; target of Rs 515: Motilal Oswal

    • Jubilant Life Sciences posts Rs 260.49 crore profit for March quarter

    • Jubilant Life Sciences signs agreement with Gilead for remdesivir

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347